Pam Skinner, Ph.D.
Cofounder and Chief Scientific Officer
Dr. Skinner, cofounder and CSO of MarPam Pharma, focuses on the development of innovative therapies for hard-to-treat diseases such as human immunodeficiency virus (HIV) infection and prion disease. For over two decades, Dr. Skinner has led successful research teams in the development of novel in situ visualization methodologies that have led to important insights in the location, abundance and phenotype of HIV- and Simian immunodeficiency virus (SIV) immunopathologies. Based on this work, Dr. Skinner recently designed and generated a chimeric antigen receptor CAR-T cell therapy to deliver targeted therapeutics to “hidden reservoirs” of SIV-infected cells in primates, showing promising results. To commercialize this therapy as a one-time treatment for the durable remission of HIV in the absence of antiviral medications, Dr. Skinner is developing a similar immunotherapeutic approach in humans to specifically target and eliminate HIV-infected cells in hidden reservoirs. Dr. Skinner’s history of numerous technical accomplishments and productive collaborations are a winning combination for MarPam Pharma’s advancements in human immunotherapies.